| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 21.612 | 18.155 | 9.369 | 5.031 | 0 | 0 | 1.213 | 1.825 | 0 | 0 |
| Total Income - EUR | 21.612 | 18.155 | 9.369 | 5.031 | 0 | 0 | 1.213 | 1.825 | 0 | 0 |
| Total Expenses - EUR | 5.758 | 8.417 | 8.311 | 1.226 | 0 | 0 | 809 | 0 | 0 | 0 |
| Gross Profit/Loss - EUR | 15.854 | 9.738 | 1.059 | 3.804 | 0 | 0 | 404 | 1.825 | 0 | 0 |
| Net Profit/Loss - EUR | 15.204 | 9.193 | 610 | 3.654 | 0 | 0 | 368 | 1.774 | 0 | 0 |
| Employees | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Noxtralys Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 30.097 | 38.649 | 10.774 | 12.338 | 12.053 | 11.824 | 11.966 | 13.792 | 13.750 | 13.673 |
| Inventories | 731 | 891 | 876 | 860 | 843 | 827 | 0 | 0 | 0 | 0 |
| Receivables | 16.017 | 15.993 | 8.580 | 8.230 | 8.071 | 7.918 | 7.742 | 7.766 | 7.743 | 7.700 |
| Cash | 13.348 | 21.765 | 1.318 | 3.248 | 3.139 | 3.079 | 4.224 | 6.025 | 6.007 | 5.974 |
| Shareholders Funds | 27.474 | 36.387 | 8.798 | 12.290 | 12.053 | 11.824 | 11.930 | 13.741 | 13.699 | 13.623 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 3.055 | 2.689 | 2.396 | 47 | 0 | 0 | 36 | 51 | 51 | 50 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6209 - 6209" | |||||||||
| CAEN Financial Year |
6209
|
|||||||||
Comments - Noxtralys Srl